ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-0T14240
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Severe Acute Respiratory Syndrome SARS Therapeutics Market Insights Forecast to 2029
BUY CHAPTERS

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Research Report 2025

Code: QYRE-Auto-0T14240
Report
January 2025
Pages:76
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Inovio Pharmaceuticals, Inc
Nanotherapeutics Inc
Novavax Inc
Phelix Therapeutics LLC
Protein Sciences Corporation

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market

The global market for Severe Acute Respiratory Syndrome (SARS) Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Severe Acute Respiratory Syndrome (SARS) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Severe Acute Respiratory Syndrome (SARS) Therapeutics.
The Severe Acute Respiratory Syndrome (SARS) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Severe Acute Respiratory Syndrome (SARS) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Report

Report Metric Details
Report Name Severe Acute Respiratory Syndrome (SARS) Therapeutics Market
CAGR 5%
Segment by Type
  • CEL-1000
  • D-3252
  • FDX-000
  • INO-4500
  • LCA-60
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Research Center
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC, Protein Sciences Corporation
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Severe Acute Respiratory Syndrome (SARS) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market report?

Ans: The main players in the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market are CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC, Protein Sciences Corporation

What are the Application segmentation covered in the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market report?

Ans: The Applications covered in the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market report are Hospital, Clinic, Research Center

What are the Type segmentation covered in the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market report?

Ans: The Types covered in the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market report are CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, Others

Recommended Reports

Respiratory Therapeutics

Infectious Disease Drugs

Diagnostics & Vaccines

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 CEL-1000
1.2.3 D-3252
1.2.4 FDX-000
1.2.5 INO-4500
1.2.6 LCA-60
1.2.7 Others
1.3 Market by Application
1.3.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Center
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Perspective (2020-2031)
2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Growth Trends by Region
2.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Dynamics
2.3.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends
2.3.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Drivers
2.3.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Challenges
2.3.4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Players by Revenue
3.1.1 Global Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue
3.4 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Concentration Ratio
3.4.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in 2024
3.5 Global Key Players of Severe Acute Respiratory Syndrome (SARS) Therapeutics Head office and Area Served
3.6 Global Key Players of Severe Acute Respiratory Syndrome (SARS) Therapeutics, Product and Application
3.7 Global Key Players of Severe Acute Respiratory Syndrome (SARS) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Breakdown Data by Type
4.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Type (2026-2031)
5 Severe Acute Respiratory Syndrome (SARS) Therapeutics Breakdown Data by Application
5.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2020-2031)
6.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2020-2025)
6.4 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2020-2031)
7.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2020-2025)
7.4 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2020-2031)
9.2 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CEL-SCI Corporation
11.1.1 CEL-SCI Corporation Company Details
11.1.2 CEL-SCI Corporation Business Overview
11.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.1.4 CEL-SCI Corporation Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
11.1.5 CEL-SCI Corporation Recent Development
11.2 GeneCure LLC
11.2.1 GeneCure LLC Company Details
11.2.2 GeneCure LLC Business Overview
11.2.3 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.2.4 GeneCure LLC Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
11.2.5 GeneCure LLC Recent Development
11.3 Humabs BioMed SA
11.3.1 Humabs BioMed SA Company Details
11.3.2 Humabs BioMed SA Business Overview
11.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.3.4 Humabs BioMed SA Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
11.3.5 Humabs BioMed SA Recent Development
11.4 Inovio Pharmaceuticals, Inc.
11.4.1 Inovio Pharmaceuticals, Inc. Company Details
11.4.2 Inovio Pharmaceuticals, Inc. Business Overview
11.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.4.4 Inovio Pharmaceuticals, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
11.4.5 Inovio Pharmaceuticals, Inc. Recent Development
11.5 Nanotherapeutics, Inc.
11.5.1 Nanotherapeutics, Inc. Company Details
11.5.2 Nanotherapeutics, Inc. Business Overview
11.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.5.4 Nanotherapeutics, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
11.5.5 Nanotherapeutics, Inc. Recent Development
11.6 Novavax, Inc.
11.6.1 Novavax, Inc. Company Details
11.6.2 Novavax, Inc. Business Overview
11.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.6.4 Novavax, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
11.6.5 Novavax, Inc. Recent Development
11.7 Phelix Therapeutics, LLC
11.7.1 Phelix Therapeutics, LLC Company Details
11.7.2 Phelix Therapeutics, LLC Business Overview
11.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.7.4 Phelix Therapeutics, LLC Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
11.7.5 Phelix Therapeutics, LLC Recent Development
11.8 Protein Sciences Corporation
11.8.1 Protein Sciences Corporation Company Details
11.8.2 Protein Sciences Corporation Business Overview
11.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.8.4 Protein Sciences Corporation Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
11.8.5 Protein Sciences Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Inovio Pharmaceuticals, Inc
Nanotherapeutics Inc
Novavax Inc
Phelix Therapeutics LLC
Protein Sciences Corporation
List of Tables
 Table 1. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of CEL-1000
 Table 3. Key Players of D-3252
 Table 4. Key Players of FDX-000
 Table 5. Key Players of INO-4500
 Table 6. Key Players of LCA-60
 Table 7. Key Players of Others
 Table 8. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
 Table 11. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2020-2025)
 Table 12. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 13. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2026-2031)
 Table 14. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Trends
 Table 15. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Drivers
 Table 16. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Challenges
 Table 17. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Restraints
 Table 18. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
 Table 19. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Players (2020-2025)
 Table 20. Global Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics as of 2024)
 Table 21. Ranking of Global Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Companies by Revenue (US$ Million) in 2024
 Table 22. Global 5 Largest Players Market Share by Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (CR5 and HHI) & (2020-2025)
 Table 23. Global Key Players of Severe Acute Respiratory Syndrome (SARS) Therapeutics, Headquarters and Area Served
 Table 24. Global Key Players of Severe Acute Respiratory Syndrome (SARS) Therapeutics, Product and Application
 Table 25. Global Key Players of Severe Acute Respiratory Syndrome (SARS) Therapeutics, Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2020-2025) & (US$ Million)
 Table 28. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2020-2025)
 Table 29. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 30. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2026-2031)
 Table 31. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2020-2025) & (US$ Million)
 Table 32. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2020-2025)
 Table 33. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 34. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2026-2031)
 Table 35. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 37. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 40. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 41. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
 Table 43. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2026-2031) & (US$ Million)
 Table 44. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 48. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 49. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 50. CEL-SCI Corporation Company Details
 Table 51. CEL-SCI Corporation Business Overview
 Table 52. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product
 Table 53. CEL-SCI Corporation Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025) & (US$ Million)
 Table 54. CEL-SCI Corporation Recent Development
 Table 55. GeneCure LLC Company Details
 Table 56. GeneCure LLC Business Overview
 Table 57. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product
 Table 58. GeneCure LLC Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025) & (US$ Million)
 Table 59. GeneCure LLC Recent Development
 Table 60. Humabs BioMed SA Company Details
 Table 61. Humabs BioMed SA Business Overview
 Table 62. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product
 Table 63. Humabs BioMed SA Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025) & (US$ Million)
 Table 64. Humabs BioMed SA Recent Development
 Table 65. Inovio Pharmaceuticals, Inc. Company Details
 Table 66. Inovio Pharmaceuticals, Inc. Business Overview
 Table 67. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product
 Table 68. Inovio Pharmaceuticals, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025) & (US$ Million)
 Table 69. Inovio Pharmaceuticals, Inc. Recent Development
 Table 70. Nanotherapeutics, Inc. Company Details
 Table 71. Nanotherapeutics, Inc. Business Overview
 Table 72. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product
 Table 73. Nanotherapeutics, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025) & (US$ Million)
 Table 74. Nanotherapeutics, Inc. Recent Development
 Table 75. Novavax, Inc. Company Details
 Table 76. Novavax, Inc. Business Overview
 Table 77. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product
 Table 78. Novavax, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025) & (US$ Million)
 Table 79. Novavax, Inc. Recent Development
 Table 80. Phelix Therapeutics, LLC Company Details
 Table 81. Phelix Therapeutics, LLC Business Overview
 Table 82. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product
 Table 83. Phelix Therapeutics, LLC Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025) & (US$ Million)
 Table 84. Phelix Therapeutics, LLC Recent Development
 Table 85. Protein Sciences Corporation Company Details
 Table 86. Protein Sciences Corporation Business Overview
 Table 87. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product
 Table 88. Protein Sciences Corporation Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025) & (US$ Million)
 Table 89. Protein Sciences Corporation Recent Development
 Table 90. Research Programs/Design for This Report
 Table 91. Key Data Information from Secondary Sources
 Table 92. Key Data Information from Primary Sources
 Table 93. Authors List of This Report


List of Figures
 Figure 1. Severe Acute Respiratory Syndrome (SARS) Therapeutics Picture
 Figure 2. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type: 2024 VS 2031
 Figure 4. CEL-1000 Features
 Figure 5. D-3252 Features
 Figure 6. FDX-000 Features
 Figure 7. INO-4500 Features
 Figure 8. LCA-60 Features
 Figure 9. Others Features
 Figure 10. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2020-2031) & (US$ Million)
 Figure 11. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application: 2024 VS 2031
 Figure 12. Hospital Case Studies
 Figure 13. Clinic Case Studies
 Figure 14. Research Center Case Studies
 Figure 15. Severe Acute Respiratory Syndrome (SARS) Therapeutics Report Years Considered
 Figure 16. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 17. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region: 2024 VS 2031
 Figure 19. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Players in 2024
 Figure 20. Global Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics as of 2024)
 Figure 21. The Top 10 and 5 Players Market Share by Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in 2024
 Figure 22. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2020-2031)
 Figure 24. United States Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2020-2031)
 Figure 28. Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. France Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2020-2031)
 Figure 36. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. India Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Australia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2020-2031)
 Figure 44. Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2020-2031)
 Figure 48. Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. CEL-SCI Corporation Revenue Growth Rate in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
 Figure 52. GeneCure LLC Revenue Growth Rate in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
 Figure 53. Humabs BioMed SA Revenue Growth Rate in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
 Figure 54. Inovio Pharmaceuticals, Inc. Revenue Growth Rate in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
 Figure 55. Nanotherapeutics, Inc. Revenue Growth Rate in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
 Figure 56. Novavax, Inc. Revenue Growth Rate in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
 Figure 57. Phelix Therapeutics, LLC Revenue Growth Rate in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
 Figure 58. Protein Sciences Corporation Revenue Growth Rate in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2020-2025)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Rabies Treatment Market Research Report 2024
Global Respiratory Antiviral Treatment Market Research Report 2024
Global Anti Infectives Market Research Report 2025
Respiratory Antivirals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Critical Care Therapeutics Market Research Report 2025
Respiratory Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Inhaled Anti Infectives Market Research Report 2025
Global Still s Disease Treatment Market Research Report 2025
Dengue Fever Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antiviral Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti infectious Disease Drugs Market Research Report 2025
Covid 19 Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Autoimmune Diseases Treatment Market Research Report 2024
Global Asthma Therapeutics Market Research Report 2025
Systemic Infection Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oncolytic Virus Drug Treatment Market Research Report 2025
Antiretroviral Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drug Safety and Pharmacovigilance Service Market Research Report 2025
Respiratory Disorders Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Respiratory Disorders Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions